The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 2 study of trastuzumab deruxtecan as neoadjuvant treatment for HER2-positive gastric and gastroesophageal junction adenocarcinoma (EPOC2003).
 
Daisuke Takahari
Honoraria - Bristol-Myers Squibb Japan; Daiichi Sankyo/UCB Japan; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Honsha
Research Funding - Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Akihito Kawazoe
Honoraria - Bristol-Myers Squibb; Daiichi Sankyo/UCB Japan; Ono Pharmaceutical; Taiho Pharmaceutical
Consulting or Advisory Role - Zymeworks
Speakers' Bureau - Bristol-Myers Squibb; Daiichi Sankyo/UCB Japan; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - AstraZeneca (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Nozomu Machida
Honoraria - Astellas Pharma; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly Japan; Merck KGaA; MSD K.K; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - ALX Oncology (Inst); Amgen (Inst); AstraZeneca (Inst); Bristol-Myers Squibb Japan (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Keiko Minashi
Research Funding - Amgen (Inst); Astellas Pharma (Inst); BeiGene (Inst); Daiichi Sankyo/UCB Japan (Inst); MSD (Inst); Ono Pharmaceutical (Inst)
 
Yukinori Yamagata
No Relationships to Disclose
 
Hiroki Hara
Honoraria - Asahi Kasei; Bayer; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo/UCB Japan; Lilly; Merck Serono; MSD; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Honsha
Consulting or Advisory Role - Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; MSD; Ono Pharmaceutical
Research Funding - ALX Oncology (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); Janssen Oncology (Inst); Merck Serono (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Takeshi Omori
Honoraria - DAIICHI SANKYO COMPANY, LIMITED
Research Funding - DAIICHI SANKYO COMPANY, LIMITED (Inst)
 
Manabu Yamamoto
No Relationships to Disclose
 
Hisateru Yasui
Honoraria - Bayer Yakuhin; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Daiichi Sankyo (Inst); MSD (Inst); Ono Pharmaceutical (Inst)
 
Izuma Nakayama
No Relationships to Disclose
 
Takanobu Yamada
Honoraria - BMS; Johnson & Johnson/Janssen; Ono Pharmaceutical; Taiho Pharmaceutical
 
Masayuki Kano
No Relationships to Disclose
 
Takaki Yoshikawa
Honoraria - Astellas Pharma; AstraZeneca; BMS; Chugai Pharma; Daiichi Sankyo; EA Pharma; Intuitive Surgical; Japan Blood Products Organization; Johnson & Johnson/Janssen; Lilly; Medtronic; Olympus; Ono Pharmaceutical; Taiho Pharmaceutical
Consulting or Advisory Role - MSD Oncology; TERUMO
Research Funding - Lilly
 
Masashi Wakabayashi
Honoraria - Nihon Medi-Physics
 
Yu Komura
No Relationships to Disclose
 
Akihiro Sato
Honoraria - AstraZeneca; Dainippon Sumitomo Pharma
Research Funding - Aspyerian Therapeutics (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo/UCB Japan (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); MSD (Inst); Oncolys BioPharma (Inst); Ono Pharmaceutical (Inst); Pentax Medical Devices (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Takeshi Kuwata
Honoraria - Astellas Pharma; Bayer; Bristol-Myers Squibb Japan; Daiichi Sankyo; FALCO biosystems; MSD; Ono Pharmaceutical; Roche
Consulting or Advisory Role - Astellas Pharma; Daiichi Sankyo; Roche
Research Funding - Roche (Inst); Takeda (Inst)
 
Motohiro Kojima
No Relationships to Disclose
 
Takahiro Kinoshita
Honoraria - Bristol-Myers Squibb Japan; Daiichi Sankyo; Gunze; Intuitive Surgical; Johnson & Johnson; Kaken Pharmaceutical; Medtronic; MSD; Olympus Medical Systems; Ono Pharmaceutical; Otsuka; Taiho Pharmaceutical; TERUMO; Tsumura & Co.
Travel, Accommodations, Expenses - Bristol-Myers Squibb Japan; Daiichi Sankyo; Johnson & Johnson K.K; Medtronic; Olympus Medical Systems; Ono Pharmaceutical; Otsuka; Taiho Pharmaceutical; Tsumura & Co.
 
Kohei Shitara
Honoraria - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Janssen; Lilly; Ono Pharmaceutical
Consulting or Advisory Role - ALX Oncology; Amgen; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Daiichi Sankyo; Guardant Health; MSD; Novartis; Ono Pharmaceutical; Takeda; Zymeworks
Research Funding - Amgen (Inst); Astellas Pharma (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); MSD (Inst); Ono Pharmaceutical (Inst); PRA Health Sciences (Inst); Taiho Pharmaceutical (Inst)